News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Winston Pharmaceuticals, Inc. (WPHM.OB) Submits NDA for CIVANEX® (Civamide Cream) for Treatment of Osteoarthritis


7/7/2010 11:10:54 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (“Winston”) (OTC PINK: WPHM), a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee. Winston anticipates that the application will be subject to a standard review with a Prescription Drug User Fee Act (PDUFA) date in the second half of 2011.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES